NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Alkeus Pharmaceuticals

Alkeus Pharmaceuticals

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://alkeuspharma.com/

Last Round

Series B

Jun 5, 2023

Total Funding Raised

$158.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Alkeus Pharmaceuticals is a biopharmaceutical company that develops innovative therapies for serious and untreatable eye diseases, including Stargardt disease and geographic atrophy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalStargardt diseasegildeuretinol acetateALK-001retinal diseaseclinical trialsorphan drugvision loss treatmentophthalmologydrug developmentbiotechrare disease drugpharma pipelineclinical stage

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alkeus Pharmaceuticals Comparables

Compare Alkeus Pharmaceuticals with similar companies based on industry and business-model similarity.

Alkeus Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ascidian Therapeutics
86%
City Therapeutics
84%
Atsena Therapeutics
84%

Alkeus Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 5, 2023
GrantSep 26, 2018
GrantOct 22, 2013
AcceleratorOct 1, 2010

Key People

Founding team and executive leadership

David Arkowitz

Chief Financial Officer

Executive Team

David Setboun

Chief Operating Officer

Executive Team

Alkeus Pharmaceuticals Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Lead compound ALK-001 granted breakthrough therapy and orphan drug status.

  • Feb 25, 2026

    Presenting data at the 49th Annual Meeting of the Macula Society.

Alkeus Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alkeus Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alkeus Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range56
Year Founded2010
Last FundingJun 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.